Ann: SARAH Abstract Embargoed Until EASL/ILC Meeting, page-70

From Bell Potter 24/3/17:-

Enhanced Understanding To Drive Revenue Growth
In our view the current share price of $17.39 can be justified from the current base of
~12,000 dose sales annually, however, if the abstract reports that the SARAH study
did not meet the primary endpoint, further price volatility is possible.
We believe the enhanced understanding of SIR spheres arising from the SARAH study
and when its use is optimal should enhance future dose sales growth and our forecast
includes this assumption. Conversely, the downside risk for revenues is reasonably
small as SIR spheres would continue to be used as salvage therapy in HCC.
There are no changes to forecast earnings at this time and we maintain our Buy​

recommendation and target price of $30.00